

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Marc Feldmann and Ravinder N. Maini

Continuation Application of

Application No.: 08/690,775

Filed: August 1, 1996

For: TNF α ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF
TNF-MEDIATED DISEASE



Date: <u>1-3-01</u>
EXPRESS MAIL LABEL NO. <u>EL 552578549US</u>

REMARKS

Box PATENT APPLICATION

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

The above-captioned application is a continuation of application number 08/690,775 ('775) filed on August 1, 1996 to which priority is claimed under 35 U.S.C. § 120.

The specification has been revised to incorporate amendments entered in the '775 application. The specification has also been revised to remove underlining and bolding of text. In certain instances, underlining has been replaced with capitalization. The specification has been amended to provide the U.S. Patent Numbers for the cited U.S. applications which have matured into patents. The related applications paragraph has been revised to include the '775 application.

The sequence listing has been amended to comply with Sequence Rules 37 C.F.R. §§ 1.821-1.825, as revised on July 1, 1998. More specifically, the sequence listing has been amended to include the docket number for the referenced application, the '775 application in the prior application data and the organism information, and to delete the correspondence address, attorney/agent information and telecommunication information. The sequence listing has also

been revised to include the amended title of the invention (see below). No new matter has been added.


Claims 1-30 of the '775 application have been omitted and remaining Claim 31 has been renumbered as Claim 1. Presently numbered Claims 2-38 have been added as new claims to the above-captioned application. Support for presently numbered Claims 2-38 can be found throughout the specification including, for example, at page 6, lines 10-15; page 8, line 22 to page 8, line 9; page 9, line 18 to page 15, line 3; and page 23, line 18 to page 25, line 7 (which correspond to page 8, lines 6-14; page 8, line 25 to page 10, line 35; page 12, line 30 to page 20, line 23; and page 32, line 30 to page 35, line 11 of the '775 application).

The title of the invention has been amended to "TNF α ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF TNF-MEDIATED DISEASE" to more specifically correspond to the claimed subject matter.

Formal drawings (8 sheets consisting of Figures 1A-1C, 2A-2C, 3A-3C, 4A-4C, 5A-5C, 6A-6C, 7A-7F and 8A-8B) have been submitted with the above-captioned application.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 
Helen Lee
Registration No. 39,270
Telephone (781) 861-6240
Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: *January 3, 2001*

2891.1001-026